Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Buprenex with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol).
The MOU is developed through a process of negotiation and mutual assent, finalized through acceptance of the MOU instrument, and approved by the appropriate agency representatives who signify such approval by signing the MOU.
Terms and Conditions of the MOU. 1  Dates. Include the date the MOU is initiated. 2  Name the Parties in the Agreement. Be very clear about who is entering the agreement. 3  Describe a Common Objective for Entering the MOU. This description provides some framework for the specifics of the MOU. 4  Describe the Expertise of Each Party.